Who is sponsoring NCT02721173?

NCT02721173 is sponsored by All India Institute of Medical Sciences, Bhubaneswar.

What condition does NCT02721173 study?

NCT02721173 studies Acne Vulgaris.

What drugs are being tested in NCT02721173?

Interventions: Tazarotene 0.1% gel plus clindamycin 1% gel, Adapalene 0.1% gel plus clindamycin 1% gel.

What is the status of NCT02721173?

NCT02721173 is currently COMPLETED.

Last reviewed 2017-01-17 · How we verify

Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial

NCT02721173 Phase 4 COMPLETED

The combination therapy of retinoid and clindamycin for acne is preferred because it targets multiple areas of acne pathogenesis that could not be accomplished with monotherapy, thereby improving outcome. Literature review reveals that till date there is no published comparative study assessing safety and efficacy of tazarotene plus clindamycin and adapalene plus clindamycin. So the present study has been designed to compare these two combination therapy in acne vulgaris.

Details

Lead sponsor	All India Institute of Medical Sciences, Bhubaneswar
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2016-04
Completion	2017-01

Conditions

Acne Vulgaris

Interventions

Tazarotene 0.1% gel plus clindamycin 1% gel
Adapalene 0.1% gel plus clindamycin 1% gel

Primary outcomes

The number of facial acne lesions — Change from baseline over 4 weeks
Total number of facial acne lesions (inflammatory and non-inflammatory) will be counted

Countries

India